BACKGROUND: Constitutive activation of STAT5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia (AML). OBJECTIVES: We investigated whether the level of phosphorylated STAT5 (pSTAT5) expression correlates with clinical outcome in AML. METHODS: Adult patients with newly diagnosed AML receiving induction chemotherapy and with an available diagnostic bone marrow were evaluated. RESULTS: Forty-two percent of patients had pSTAT5 expression >0 on immunohistochemical analysis of fixed bone marrow core biopsies. In multivariable analyses, controlling for age, history of antecedent hematologic disorder, cytogenetic risk, and WBC at diagnosis, pSTAT5 expression was significantly associated with an increased risk of death (HR 1.96, 95% CI 1.19-3.23, P = 0.008) and of relapse after achieving complete remission (HR 2.31, 95% CI 1.16-4.63, P = 0.018). CONCLUSIONS: Validation of pSTAT5's prognostic value requires additional study in a larger group of uniformly treated patients. However, our data suggests that targeting this signaling pathway in AML may improve the outcome of patients.
BACKGROUND: Constitutive activation of STAT5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia (AML). OBJECTIVES: We investigated whether the level of phosphorylated STAT5 (pSTAT5) expression correlates with clinical outcome in AML. METHODS: Adult patients with newly diagnosed AML receiving induction chemotherapy and with an available diagnostic bone marrow were evaluated. RESULTS: Forty-two percent of patients had pSTAT5 expression >0 on immunohistochemical analysis of fixed bone marrow core biopsies. In multivariable analyses, controlling for age, history of antecedent hematologic disorder, cytogenetic risk, and WBC at diagnosis, pSTAT5 expression was significantly associated with an increased risk of death (HR 1.96, 95% CI 1.19-3.23, P = 0.008) and of relapse after achieving complete remission (HR 2.31, 95% CI 1.16-4.63, P = 0.018). CONCLUSIONS: Validation of pSTAT5's prognostic value requires additional study in a larger group of uniformly treated patients. However, our data suggests that targeting this signaling pathway in AML may improve the outcome of patients.
Authors: Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur Journal: Cell Rep Date: 2014-11-13 Impact factor: 9.423
Authors: Yiting Lim; Lukasz Gondek; Li Li; Qiuju Wang; Hayley Ma; Haley Ma; Emily Chang; David L Huso; Sarah Foerster; Luigi Marchionni; Karen McGovern; David Neil Watkins; Craig D Peacock; Mark Levis; Bruce Douglas Smith; Akil A Merchant; Donald Small; William Matsui Journal: Sci Transl Med Date: 2015-06-10 Impact factor: 17.956
Authors: Claudia Oancea; Brigitte Rüster; Boris Brill; Jessica Roos; Maria Heinssmann; Gesine Bug; Afsar Ali Mian; Nathalie Andrea Guillen; Steven M Kornblau; Reinhard Henschler; Martin Ruthardt Journal: Genes Cancer Date: 2014-11
Authors: Hongliang Zong; Alexander Gozman; Eloisi Caldas-Lopes; Tony Taldone; Eric Sturgill; Sarah Brennan; Stefan O Ochiana; Erica M Gomes-DaGama; Siddhartha Sen; Anna Rodina; John Koren; Michael W Becker; Charles M Rudin; Ari Melnick; Ross L Levine; Gail J Roboz; Stephen D Nimer; Gabriela Chiosis; Monica L Guzman Journal: Cell Rep Date: 2015-11-25 Impact factor: 9.423